Igalmi (Dexmedetomidine HCl) Patent Expiration, LOE Window & CMS Spending

Igalmi (Dexmedetomidine HCl) by Bioxcel Therapeutics: FDA Orange Book LOE 2043-01-12, 0 AB generics, $720K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBioxcel Therapeutics
FDA Application & PathwayN215390 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2043-01-12
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$720K
2024 Medicare Part D Spend$309K
2024 Medicaid Spend$411K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel